Prascend is a synthetic ergot derivative and is a potent dopamine receptor agonist. As with other dopamine agonists, Prascend inhibits the release of prolactin. In horses with PPID, Prascend is believed to exert its therapeutic effect by stimulating dopamine receptors, and has been shown to decrease the plasma levels of adrenocorticotropic hormone (ACTH), melanocyte stimulating hormone (MSH), and other pro-opiomelanocortin peptides.
Prascend tablets may be administered orally by dissolving the tablet with a small amount of water and/or mixing with molasses or other sweetener; taking care to rinse the dosing apparatus with water to ensure entire dose of Prascend is administered; use immediately. Most horses respond to Prascend therapy and are stabilised at an average dose of 2 µg/kg.
Normally it takes 6 to 8 weeks until clinical signs improve. Improvement of clinical signs is not necessarily correlated to an improvement of endocrinologic test results. The earliest signs are improvement in the overall attitude and behavior of the horse (e.g. horses become more active) is usually observed within 30 to 60 days of treatment institution.